December 9, 2022
NDTV News


Almost 50-60 per cent kids who got here for Covid vaccine trials had antibodies, Dr Randeep Guleria stated.

New Delhi:

In two-to-three months from now, consultants in India will know if Bharat Biotech’s Covaxin works on kids as younger as two. The technique of testing the vaccine’s efficacy in opposition to Covid has begun, Dr Randeep Guleria, Director of the All-India Institute of Medical Sciences (AIIMS) Delhi, has stated.

“Bharat Biotech is looking at vaccinating children of 2 years to 18 years. It has already started…a number of children have already been vaccinated,” Dr Guleria informed NDTV.

“Over the next 2-3 months we should be able to say whether these vaccines work in children even as young as two years old. And then they should get regulatory approval. Pfizer already has the regulatory approval but for a little older age group,” he stated.

AIIMS Delhi and Patna have already begun recruiting and holding trials on kids for a Covid vaccine.

Dr Guleria additionally stated {that a} vital variety of kids who got here to be recruited for the trials already had antibodies in them, significantly bettering their probabilities within the subsequent potential upsurge of infections.

Current information, in keeping with Dr Guleria, nonetheless means that mortality is greater within the aged and in these with co-morbidities as in comparison with kids. The focus, he insists, should firmly stay on this class.

“If you look at even vaccine recruitment data and some data published by us as part of the trial, a significant number of children already had antibodies in them, although there was no evidence of infection,” Dr Guleria informed NDTV.

“Almost 50-60 per cent of those who came for trials couldn’t be recruited because they had antibodies…What this suggests is that they have a good amount of immunity. This worry that ‘the next wave may affect them’ may not be correct,” Dr Guleria stated.

Referring to the emergence of Delta Plus as a Covid variant of concern, the veteran physician stated the variety of instances presently was too few to come back to a conclusion over its significance when it comes to severity of illness, mortality, or the impact of antibodies.

He, nonetheless, emphasised vigilance in order that the nation just isn’t caught off-guard because the virus mutates.

“We shouldn’t be lagging behind in terms of actions we need to take in case this variant becomes more infectious and starts spreading,” he stated.

Leave a Reply

Your email address will not be published. Required fields are marked *